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Introduction/objectives: The role of the placenta in diabetic mothers on fetal development and programming is
unknown. Prolactin (PRL) produced by decidual endometrial cells may have an impact. Although full-length
PRL is angiogenic, the processed form by bone morphogenetic protein-1 (BMP-1) and/or cathepsin D (CTSD) is
antiangiogenic.
The objectiveswere to investigate the involvement of decidual PRL and its antiangiogenic fragments in placentas
from type-1 diabetic women (T1D) and from pregnant diabetic rats with lower offspring weights than controls.
Methods: PRL, BMP-1, and CTSD gene expressions and PRL protein level were assessed in T1D placentas (n=8) at
delivery and compared to controls (n=5).Wistar rats received, at day 7 of pregnancy, streptozotocin (STZ) (n=
5) or nicotinamide (NCT) plus STZ (n=9) or vehicle (n=9). Placental whole-genome gene expression and PRL
western blots were performed at birth.
Results: In human placentas, PRL (p b 0.05) and BMP-1 (p b 0.01) gene expressions were increasedwith a higher
amount of cleaved PRL (p b 0.05) in T1D than controls. In rats, diabetes was more pronounced in STZ than in
NCT–STZ group with intra-uterine growth restriction. Decidual prolactin-related protein (Dprp) (p b 0.01) and
Bmp-1 (p b 0.001) genes were up-regulated in both diabetic groups, with an increased cleaved PRL amount in
the STZ (p b 0.05) and NCT–STZ (p b 0.05) groups compared to controls. No difference in CTSD gene expression
was observed in rats or women.
Conclusions: Alterations in the levels of the PRL family are associatedwithmaternal diabetes in both rats and T1D
women suggesting that placental changes in these hormones impact on fetal development.© 2014 Elsevier B.V. All rights reserved.1; CTSD, cathepsin D; D, day of
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).1. Introduction
Maternal diabetes (MD) accounts for a variety of fetal adverse
effects, including spontaneous abortion, intrauterine fetal death,
andmaternal and perinatal complications (preeclampsia, prematuri-
ty, neonatal respiratory distress syndrome) associated with abnor-
mal birth weight [1], and depends on the severity of diabetes [2],
especially when vascular complications are present [3]. The perinatal
period represents a critical window of vulnerability to the environ-
ment [4] and can modulate health conditions later in life [5,6]. MD
induces damage to placenta [7,8] but the molecular mechanisms
involved are still elusive.
The placenta produces numerous hormones including prolactin
(PRL). PRL is released fromdecidualized endometrial cells, and is thought
to regulate the immune system [9,10], amniotic-ﬂuid homeostasis [10,
1784 P. Perimenis et al. / Biochimica et Biophysica Acta 1842 (2014) 1783–179311], and placental angiogenesis [12,13] at the feto-maternal interface.
PRL stimulates cell migration and invasion in human trophoblast
in vitro [14]. Angiogenesis is crucial for trophoblast invasion [15] and
feto-placental growth [16]. Findings report that endothelial cells produce
and release PRL [17].
In this regard, full-length proangiogenic PRL (23-kDa) proteolysis
generates N-terminal fragments, products known to be antiangiogenic
andproapoptotic, and are also known as vasoinhibins [13,17–20]. Sever-
al candidate proteases have been reported in rodents and/or in humans:
i.e., certain metalloproteinases (MMPs) [21], bone morphogenetic-
protein-1 (BMP-1) in neutral conditions [22], or cathepsin D (CTSD) in
acid environment [23,24].
PRL and/or its vasoinhibins are thought to be involved in preeclamp-
sia [12,13,25,26].More recently, in a cohort of 501preeclampticwomen,
the risk of small-for-gestational-age (SGA) infants was increased when
vasoinhibins were present in the amniotic ﬂuid [13]. Immunemaladap-
tation to pregnancy may contribute to predominant 16-kDa PRL decid-
ual production [25].
The decidual production coupled to the involvement in placental
angiogenesis and preeclampsia, with an increased risk for SGA infants,
suggests that decidual PRL (dPRL) and/or its fragments could play a
role in MD at the feto-maternal interface.
The aim of our studywas to investigate the involvement of dPRL and
its antiangiogenic fragments in placentas from type-1 diabetic women
(T1D) and pregnant diabetic rats with lower offspring weights than
controls.
2. Methods
2.1. Collection of human placentas
Placentas were obtained from controls (n = 5) and women with
T1D (n = 8) at birth, who were recruited from the Hospital Regional
Center (CHRU)of Lille (France). For each placenta, sampleswere obtain-
ed from4 various locations between the decidual and chorionic plates in
order to limit the tissue heterogeneity, near the umbilical cord on the
fetal side and pooled for gene expression or protein analyses or used in-
dividually for immunohistochemical analyses. The sampling location
was uniform, performed by the same technical assistant.
All the diabetic women were managed with standardized protocols
regarding the treatment of diabetes, especially insulin therapy and
prenatal care. Control women were deﬁned by having normal glucose
tolerance and a newbornwith a normal birthweight. This studywas ap-
proved by the ethics committee of the CHRU of Lille (DG7 2007-0340/
CCP07/43). All women involved received verbal information about the
study and gave their written informed consent before examination.
2.2. Animal study
Female Wistar rats (200–250 g, Janvier, Le Genest Saint Isle, France)
were housed individually with a controlled 12/12 h light/dark cycle, at
22 ± 1 °C, and were fed ad libitum with a standard chow diet. On the
7th day (D) of gestation, three groups of animals were formed, i.p.
injected sequentially after 15 min: a diabetic group with severe hyper-
glycemia (the STZ group: n = 5, received vehicle (NaCl 0.9%) and
streptozotocin (STZ) [65 mg/kg, dissolved in citrate buffer 0.1 mmol/l,
pH 4.5; Sigma-Aldrich, St Quentin-Fallavier, France]); a diabetic group
with moderate hyperglycemia (NCT–STZ group: n= 9, received nico-
tinamide [NCT, Sigma-Aldrich, 75 mg/kg dissolved in NaCl 0.9%] and
STZ [65 mg/kg]); and a control group (C group: n = 9, received the
same volume of two vehicles). By injecting STZ and NCT at day 7 of ges-
tation, we aimed to prevent the early formation of the fetal pancreas. In
addition, at this stage, STZ induces MD without directly affecting fetal
pancreas. The GLUT2 glucose transporter, through which STZ triggers
beta cell destruction, is not expressed in the early pancreas develop-
ment [27,28].Daily capillary blood-glucose (ACCU-CHEK Performa Glucometer,
Roche Diagnostics, Mannheim, Germany) and weight were evaluated
from D7–18 in dams. At D19, for all groups, an oral glucose-tolerance
test was performed after 16 h of fasting. Animals received 2 g/kg of
glucose, and blood samples were collected from the tail vein at 0, 30,
60, 90, and 120min to assess glucose (ACCU-CHEK Performa glucometer)
and insulin (insulin Rat kit ELISA, Mercodia, Uppsala, Sweden) levels.
All animal experiments were conducted in accordance with the
European Communication Council Directive of November 24, 1986
(86/609/EEC).
2.3. Collection of blood and tissue samples from rats
Pregnant rats were sacriﬁced before delivery at D21, corresponding
to the end of pregnancy, andmaternal bloodwas collected to assess glu-
cose (ACCU-CHEK Performa glucometer), insulin (insulin rat kit, ELISA),
and PRL (rat prolactin ELISA kit, CUSABIO BIOTECH, China) plasma
levels. Fetuses were removed with their respective placentas and sepa-
ratelyweighed. Placentaswerewashed several times in Phosphate Buff-
ered Saline (PBS) to eliminate red blood cells and transferred in
RNAlater (Qiagen, Courtaboeuf, France) for gene expression analysis,
or were snap-frozen in liquid nitrogen and stored at−80 °C for protein
analysis, or were ﬁxed in 4% paraformaldehyde (without previous
washing in PBS) for histological analysis. Fetuses' pancreases were re-
moved and ﬁxed in 4% paraformaldehyde. Placentas and pancreases,
ﬁxed in 4% paraformaldehyde, were parafﬁn-embedded (Paraplast
Plus, McCormick LLC, St. Louis, MO, USA). Fetuses' blood samples were
collected for the determination of glucose levels (ACCU-CHEK) and
plasma samples in each litter were pooled to assess insulin levels
(insulin rat kit, ELISA).
2.4. Gene-expression analyses of human and rat placentas
2.4.1. Extraction of RNA
Placental samples from women were transferred in RNAlater
(Qiagen, France). For rats, ﬁve placentas were randomly selected from
each dam and placentas from each group were pooled together for mi-
croarray analysis or used individually for qRT-PCR validation.
Total RNAwas isolated using the RNeasy® kit (Qiagen). The quanti-
ﬁcation and quality of RNA were assessed by spectrophotometric anal-
ysis with NanoDrop (Thermo Fischer Scientiﬁc, Illkirch, France) and by
Agilent Bioanalyzer capillary electrophoresis system (Agilent technolo-
gies France, Massy, France), respectively. Measurements were carried
out with a Bioanalyzer using RNA integrity number (RIN): the correlat-
ing electropherogram and gel-like image were generated for each
sample. The RIN was obtained prior to array hybridization. Only high-
quality RNA (RIN N 8) was used for analysis.
2.4.2. Quantitative RT-PCR (qRT-PCR) gene-expression analysis of human
placentas
For humans, total RNA from each placenta was reverse-transcribed
to cDNA using a cDNA synthesis kit (ThermoScript™ RT-PCR System
for First-Strand cDNA Synthesis, Invitrogen, France). qRT-PCR was
run in duplicate using a LightCycler 480 SYBR Green I Master Mix
(Roche Diagnostics, Meylan, France), primers (Table 1), and a real-
time PCR system (Thermocycler LightCycler LC 2.0 Roche, France).
Gene expression was normalized with the TATA box-binding protein
gene.
2.4.3. Rat placenta microarray procedure and qRT-PCR gene-expression
analysis
Whole-gene expression proﬁling, using the Illumina Rat Ref-12
BeadChip (22523 probes for a total of 21792 genes from NCBI RefSeq;
Illumina, San Diego, CA, USA), was carried out according to standard
procedures. Aliquots of 300 ng of total RNA were reverse-transcribed
to cDNA, transcribed to cRNA, ampliﬁed and biotin-labeled with a
Table 1
Human primers sequences used for RT-PCR.
Hu: homo sapiens.
ID name Forward primer Reverse primer Gene name
Hu PRL 5′ACCAGGAAAAGGGAAACGAATGCC 3′ 5′CGTTGCAGGAAACACACTTCACCA3′ Prolactin
Hu BMP-1 5′TTCTCAGACAAGGACGAGTGCTCC3′ 5′TGCCGAACGTGTTGACGCA-GT 3′ Bone morphogenetic protein 1
Hu CTSD 5′CAGGGCGAGTACATGATCCC3′ 5′TTGTAGCCTTTGCCTCCCAG3′ Cathepsin D
Hu TBP 5′ACGCCAGCTTCGGAGAGTT3′ 5′ GCACGAAGTGCAATGGTCTTT3′ TATA box binding protein
1785P. Perimenis et al. / Biochimica et Biophysica Acta 1842 (2014) 1783–1793Target Amp Nano-g Biotin-aRNA labeling kit for the Illumina System
(Epicentre Biotechnologies, Madison, WI, USA), and puriﬁed with
RNeasy MinElute Cleanup Kit (Qiagen). Biotinylated cRNA probes were
hybridized on BeadChips, incubated for 16 h at 58 °C, streptavidin-Cy3-
labeled and processed on an Illumina BeadArray Reader. Normalized
bead-intensity data (using the cubic spline-normalization method)
were analyzed with Illumina GenomeStudio software. Gene-expression
data were loaded into GeneSpring (Agilent Technologies France, Massy,
France) for management, analysis, and interpretation. Pathway analysis
was conducted with Ingenuity Pathway Analysis (IPA) Software
(Ingenuity Systems, RedwoodCity, USA). A list of differentially expressed
genes was identiﬁed using one-way ANOVA followed by Tukey's post-
hoc test. Differences were considered signiﬁcant at p b 0.05 and a
mean difference greater than 1.4-fold.
qRT-PCR TaqMan was used to conﬁrm the expression of selected
genes from transcriptomic analysis. Each assay was run in triplicate
for each RNA sample from the rat placentas. Total RNA was reverse-
transcribed using a high-capacity cDNA RT kit (Applied Biosystems,
Foster city, CA). Assays were run with Universal Master Mix (Applied
Biosystems) using TaqMan probes for selected genes (Table 2) on an
Applied Biosystems 7900HT detection system (cycling program includ-
ed 10 min incubation at 95 °C, followed by 40 cycles at 95 °C). Data
values (Cycle Threshold values) were extracted from each assay with
the SDS software tool (Applied Biosystems). Gene expression was
normalized with the beta-2 microglobulin (B2M) gene.2.5. Human and rat placenta western-blot analysis
Equal amounts of proteins (70 μg) from the placentas from the
two human groups and the three animals groups were loaded into
12% SDS-PAGE. For the rat study, three to ﬁve placentas were ran-
domly selected from each dam. Western-blot analysis was per-
formed using rabbit anti-PRL (1:200, Santa Cruz Biotechnology)
and β-actin (1:5000, Sigma) for human placentas or a mouse anti-
alpha-tubulin (1:5000, Sigma) antibody for rat placentas. Extracted
PRL from rat pituitary gland was used as positive control. After
being transferred on a nitrocellulose membrane (Hybond-ECL,
Amersham BioSiences, Chalfont, UK), the proteins were detected
using horseradish-conjugated secondary antibody (1:5000; Santa
Cruz Biotechnology) and Chemiluminescence Supersignal (Pierce).
Densitometric analysis was performed using ImageJ software
(National institutes of Health, Maryland, USA) and data were nor-
malized for alpha-tubulin or β-actin.Table 2
TaqMan probes used for RT-PCR in rat placentas.
Rat: rattus norvegicus.
ID name Assay ID
Rat Bmp1 Rn01466024_m1
Rat Dprp Rn00575655_m1
Rat Ctsd Rn00592528_m1
Rat B2M Rn00560865_m12.6. Histological and immunohistochemical analyses from rats and humans
2.6.1. Rat pancreas immunochemistry
From each dam, the pancreas fromone to three fetuseswas random-
ly selected for each different immunostaining. Five-μm-thick sections
were deparafﬁnized in xylene and rehydrated through a graded series
of ethanol. Antigen retrieval was performed by warming the sections
for 5 min at 96 °C in citrate buffer (pH 6).
After a cooling period of 30 min, sections were incubated with a
mouse anti-insulin antibody (1:500, AbDSerotec, Colmar, France), rab-
bit anti-glucagon (DAKO), and rabbit anti-pancreatic and duodenal ho-
meobox 1 (Pdx1) (1:500, Abcam, Paris, France). Sections were then
washed in Tris-buffered saline and incubated for 30 min at room tem-
perature with Alexa 488 coupled goat anti-mouse (for insulin), Alexa
488 goat anti-rabbit (for Pdx1), and Alexa 594 anti-rabbit (for glucagon)
antibodies (1:500, Life Technologies). The samples were analyzed by
inverted ﬂuorescence microscopy (Zeiss, Oberkochen, Germany). For
non-ﬂuorescent evaluation of islets, slides, following incubation with
the insulin anti-mouse antibody, were washed and incubated for 1 h
with a biotinylated sheep-anti-mouse antibody (1:2000, Chemicon, Te-
mecula, CA, USA). They were then washed and incubated for 1 h with a
streptavidin–peroxidase antibody (1:2000, Amersham, Buckinghamshire,
UK), and revealed with 3,3′diaminobenzidine tetra-hydrochloride-DAB
(Sigma-Aldrich).2.6.2. Rat and human placental histology
Placental samples from women were parafﬁn-embedded. For rats,
from each dam, the placenta from one to three term fetuses was ran-
domly selected for each different histological or immunohistochemical
analysis. Five-μm-thick sections were deparafﬁnized in xylene and
rehydrated through a graded series of ethanol. Sections were stained
with Hematoxylin–Eosin or incubated with a monoclonal mouse anti-
CD31 antibody (1:40, DAKO, Glostrup, Denmark) using Ventana kits
(Ventana, Tucson, Arizona, USA) according to instructions for both spe-
cies placentas or with Periodic Acid Schiff (PAS)-diastase for only rat
placentas.
Vascular areas were estimated using ImageJ software (National In-
stitutes of Health). In rat and women placenta, capillary density was es-
timated by a combination of CD31 staining for the distinction between
maternal and fetal blood and of morphological analyses by mm2 in the
labyrinth zone in rat placenta and in terminal villi in women placentas.
Capillary diameter (μm) was estimated by counting with an ocular mi-
crometer from 10 ﬁelds of view. In women placentas, capillary densityAccession number Gene name
NM_031323.1 Bone morphogenetic protein 1
NM_022846.1 Decidual prolactin-related protein
NM_134334.2 Cathepsin D
NM_012512.2 Beta-2 microglobulin
Table 3
Patient characteristics.
BMI: body mass index; NA: not available; NS: not signiﬁcant; HbA1C: glycated hemoglobin. Data are means ± SEM. *p b 0.05.
Characteristics Controls (n = 5) Diabetics (n = 8) p-Value
Women age, years 28.80 ± 2.78 27.88 ± 1.69 NS
Duration of diabetes, years – 14.75 ± 3.44 –
Women's preconception BMI, kg/m2 21.15 ± 0.64 24.95 ± 1.64 NS
1st trimester women's HbA1C, % NA 6.85 ± 0.44 –
2nd trimester women's HbA1C, % NA 6.41 ± 0.27 –
3rd trimester women's HbA1C, % NA 6.45 ± 0.25 –
Gestational age, weeks 39.20 ± 0.37 38.38 ± 0.42 NS
Newborn birth weight, g 3366 ± 94.05 3026 ± 100.1 *p b 0.05
Placental birth weight, g 428.0 ± 16.11 428.0 ± 17.80 NS
Placental efﬁciency ratio 7.91 ± 0.37 7.10 ± 0.29 NS
1786 P. Perimenis et al. / Biochimica et Biophysica Acta 1842 (2014) 1783–1793was estimated by counting in terminal villi. Capillary structures were
deﬁned as CD31-positive capillary endothelial cells.
2.7. Statistical analyses
Data are presented as their means ± SEMs. All statistical analyses
were performed using GraphPad Prism 5.0 software (San Diego, USA).
Comparisons between women groups were performed using the non-
parametric Mann–Whitney test. Comparisons between rat groups
were performed using one-way ANOVA followed by Tukey's post-hoc
test. A p-value of ≤0.05 was considered statistically signiﬁcant.
3. Results
3.1. Birth weight was lower in newborns from diabetic mothers
The women's characteristics are summarized in Table 3. Control and
diabetic subjects were similar regarding age, bodymass index, and ges-
tational age at delivery. T1D women had no diabetic vascular complica-
tions, no hypertension and their HbA1c level was 6.45 ± 0.25%
(47 mmol/mol) at delivery with a good glycemic control during the en-
tire pregnancy. Birth weight was signiﬁcantly lower in newborns from
diabeticmothers (3026± 100.1 g) compared to newborns from control
women (3366± 94.05 g) (p b 0.05). No differencewas found in placen-
tal birth weight between the two groups studied. The ratio of fetal
weight to placental weight used to evaluate the placental efﬁciency
did not vary between the two groups.
3.2. PRL is increased at mRNA and protein levels in the placentas from DT1
women
We evaluated the effects of diabetes on gene expression of PRL and
on its protein level in the placenta. A signiﬁcant increase in PRL was
observed in the diabetic group compared to control at mRNA level
(Fold Change (FC) ≈ 9, p b 0.05) (Fig. 1A) and conﬁrmed at protein
level with an increased total PRL amount (p b 0.01) (Figs. 1B and C).
3.3. Expressions of BMP-1 and PRL cleavage are increased in the placentas
from DT1 women
We evaluated if diabetes affected the PRL cleavage and generated an
increased vasoinhibin amount at protein level and if cleavage proteases,
BMP-1 and/or CTSD could be involved in this process. As anticipated,
western-blot analysis showed native full-length (23-kDa) and cleaved
forms of PRL within the total protein extracts from human placentas
(Fig. 1B). The ratio of cleaved PRL to full-length PRL (p b 0.05)
(Fig. 1D) was signiﬁcantly increased in placentas from diabetic patients
compared to controls with an increased processed form amount. BMP-1
(FC≈ 13, p b 0.01) gene expression was effectively increased (Fig. 1E)
in diabetic placentas compared to controls. However, CTSD gene expres-
sion in both groups was similar (Fig. 1E).As vasoinhibins play a role in angiogenesis, we performed immuno-
histochemical analyses to study vasculature. Hematoxylin and Eosin
stained sections showed an up to 10% reduction in vascular surfaces in
diabetic placentas compared to the controls (Fig. 1F) and demonstrated
structural differences of terminal villi. Normal terminal villi are of small-
er diameter than diabetic villi. CD31 was used as an endothelial marker
for quantifying fetal capillaries. Capillary density was reduced in the di-
abetic sections (6.16 ± 0.32, p b 0.05) (Fig. 1G) compared to controls
(7.02 ± 0.26) with a smaller diameter of the capillaries (6.03 ±
0.36 μm, p b 0.05) (Fig. 1H) compared to controls (7.22 ± 0.44 μm) in
terminal villi.
3.4. Intra uterine growth restriction (IUGR) in rat diabetic models
Pregnant rats were injectedwith STZ or NCT–STZ to obtain severe or
moderate diabetic conditions in rat models. During gestation, the dams'
weight gain in the three groups was not signiﬁcantly different until
D14. After D14, only the STZ-treated dams lost weight signiﬁcantly
(p b 0.05). By D21, the dams' weight in STZ (p b 0.001) and NCT–STZ
(p b 0.05) groups was signiﬁcantly lower compared to that in the con-
trol group (Fig. 2A).
As expected, dams that received STZ (p b 0.001) or NCT–STZ (p
b 0.001) developed signiﬁcant hyperglycemia compared to the controls
by 24 h after STZ injection (Fig. 2B), which was more severe in the STZ
group (p b 0.05) than in the NCT–STZ group for thewhole period of ges-
tation. By D19, fasting blood-insulin was signiﬁcantly reduced in the
two diabetic groups (0.14 ± 0.02 μg/l in the STZ group, 0.23 ±
0.05 μg/l in the NCT–STZ group) compared to the controls (0.93 ±
0.214 μg/l, p b 0.001). There was no signiﬁcant difference in plasma-
insulin values between the STZ and NCT–STZ groups (data not shown).
We evaluated the level of plasma PRL in control and diabetic dams.
Maternal plasma PRL level at D21 was signiﬁcantly higher in the STZ
(29.19 ± 3.61 ng/ml, p b 0.01) and NCT–STZ (18.81 ± 2.89 ng/ml, p
b 0.01) groups compared to the controls (4.47 ± 0.45 ng/ml) (Fig. 2C).
We analyzed fetuses' weight and their placenta at D21. Fetuses' birth
weight was signiﬁcantly reduced in both diabetic groups (STZ: 3.55 ±
0.14 g, p b 0.001; NCT–STZ: 4.18 ± 0.09 g, p b 0.001) when compared
to the control group (5.57 ± 0.04 g) (Fig. 3A) and this reduction was
more severe in STZ group than NCT–STZ group (p b 0.001). The
placental weight was signiﬁcantly increased in the STZ (0.73 ±
0.02 g, p b 0.001) and NCT–STZ (0.63 ± 0.01 g, p b 0.001) groups
compared to the controls (0.56±0.01 g) (Fig. 3B)with a placental hyper-
trophy more pronounced in STZ group than NCT–STZ group (p b 0.001).
The ratio of fetal weight to placental weight was signiﬁcantly reduced in
both diabetic groups (STZ: 5.04± 0.22, p b 0.001; NCT–STZ: 6.83± 0.20,
p b 0.001) compared to the controls (10.10 ± 0.14). In line with the
placental hypertrophy, stained PAS-diastase sections of STZ, NCT–STZ
and control placentas showed glycogen accumulation in the tropho-
blastic cells of the hemo-placental barrier in the two diabetic groups
compared to the controls (Fig. 3C). No edema or ischemic zones were
observed.
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Fig. 1. Analysis of PRL gene expression and cleavage in human placentas. Placental mRNA expression of prolactin (PRL) (A). Representative western-blot analysis of prolactin proteolytic
products in placentas (B). Relativemolecular mass of each band is shown on the left. Quantiﬁcation of total amounts of PRL fragments (C) and of cleaved PRL to 23-kDa PRL ratio (D) from
western-blot data. Cleaved PRL represents the sum of≈17-kDa PRL and≈15-kDa PRL fragments amounts. Placental mRNA expressions of bone morphogenetic protein-1 (BMP-1) and
cathepsinD CTSD (E). Placental histological sections stained byHematoxylin–Eosin (HE) and placental CD31 immunostaining (F), stereological analyses of fetal capillary network showing
capillary density (G) and themean capillary diameter (H) in terminal villi. Magniﬁcation ×200 and in the square ×400. Data are expressed asmeans± SEM and are signiﬁcantly different
at *p b 0.05; **p b 0.01.
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D21, fetuses from STZ and NCT–STZ groups were hyperglycemic
(25.52 ± 1.09 mmol/l, p b 0.001 and 20.02 ± 0.63 mmol/l, p b 0.001,
respectively) compared to those of the controls (3.82 ± 0.10 mmol/l)
(Fig. 4A). Neonatal plasma-insulin levels were lower in both diabetic
groups (0.33 ± 0.09, p b 0.001 and 0.49 ± 0.10 mmol/l, p b 0.01 for
STZ and NCT–STZ groups, respectively) with greater severity in the
STZ group compared to the controls (0.76 ± 0.07 mmol/l) (Fig. 4B).Plasma-insulin level was not statistically different but tended to be
lower in the STZ group compared to the NCT–STZ group. We performed
immunoﬂuorescence staining of pancreases from fetuses (Fig. 4C). Islet
ultrastructure from control fetuseswas normal. Insulin and Pdx1 immu-
nostaining of islets was intense and homogeneous: i.e., in the mantle of
glucagon-positive cells surrounding the insulin-positive cells. In sharp
contrast, the number of islets in NCT–STZ and STZ fetuses was reduced,
but the STZ group was more severely affected than the NCT–STZ group.
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1788 P. Perimenis et al. / Biochimica et Biophysica Acta 1842 (2014) 1783–1793Insulin and Pdx1 immunostaining was profoundly reduced in the
STZ group compared to controls or the NCT–STZ group. However,
there was no difference between the NCT–STZ and control groups.
Glucagon-positive cells were preserved in the two diabetic groups
compared to the controls. Lower insulin blood levels in pups are due
in part in a reduction in beta cell mass as we demonstrated a reduction
in insulin and Pdx 1 immunostaining in the diabetics groups. As expect-
ed, this reduction wasmore pronounced in STZ group due to protective
effect of the NCT in NCT-STZ group.
3.5. Dprp gene expression increases in placentas from diabetic rat models
A microarray differential transcriptome analysis was performed to
explore global gene-expression proﬁling and the involvement of thePRL family members in our diabetic models. We showed modiﬁcation
in 693 mRNA in the placentas from rats treated with STZ. Among
the modiﬁed mRNA, 325 were up-regulated and 368 were down-
regulated. When compared to the controls, 677 mRNA were modiﬁed
in the placentas from the NCT–STZ group: 301 were up-regulated and
376were down-regulated. Compared to the control group, gene expres-
sion was similar in both diabetic groups for 457 mRNA (243 were up-
regulated and 214 were down-regulated), and was different in 98
mRNA (59 up-regulated and 39 down-regulated). We analyzed some
of the gene functions of the 457 mRNA that were expressed similarly
in both diabetic groups (compared to controls) using IPA software.
Most of these genes were involved in “cell growth/proliferation”, and
“cellular mobility”, or “lipid metabolism” (Fig. 5A). Function analysis
of the up- and down-regulated mRNAs is shown in Fig. 5B and C.
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related protein (Dprp) (also known as Prl8a2) gene expression, con-
ﬁrmed by qRT-PCR was approximately 4-fold increased in the STZ
(p b 0.01) and NCT–STZ (p b 0.01) groups compared to the controls
(Fig. 6); all other members that included Prl gene expression did
not differ between groups.
No difference was also noted at protein level by western blot analy-
sis of PRL between all groups (data not shown).
3.6. Bmp-1 gene expression and PRL cleavage are increased in the placentas
from diabetic rat models
Bmp-1, by qRT-PCR,was up-regulated in STZ (FC≈ 1.5, p b 0.05) and
NCT–STZ (FC≈ 2, p b 0.001) groups compared to the controls. Howev-
er, therewas nodifference in the Bmp-1 gene expression levels between
the diabetic groups. Ctsd gene expression did not vary between any of
the groups (Fig. 7A).
Bywestern blot, the unprocessed (23-kDa) and cleaved forms of PRL
were also evident in rat placentas (Fig. 7B). The ratio of cleaved PRL to
full-length PRL was signiﬁcantly higher in the STZ (p b 0.05) and NCT–
STZ (p b 0.05) groups compared to the controls (Fig. 7C).
As vasoinhibins play a role in angiogenesis, we performed histo-
logical analysis to study vascular surfaces. Hematoxylin and Eosin
stained sections showed an up to 20% reduction in vascular surfacesin STZ and NCT–STZ placentas compared to the controls (Fig. 7D).
Using CD31 to differentiate fetal capillaries frommaternal blood, ste-
reological analyses of the placental labyrinth zone showed a reduc-
tion in capillary density in the STZ (15 ± 1.08, p b 0.01) and NCT–STZ
(15 ± 1.00, p b 0.01) sections compared to controls (23 ± 0.57)
(Fig. 7E) with a smaller diameter of the capillaries in STZ (5.37 ±
0.26 μm, p b 0.001) and NCT–STZ (5.57± 0.23 μm, p b 0.001) compared
to controls (10.37 ± 0.55 μm) (Fig. 7F).
4. Discussion
Our study was designed to uncover the potential contribution
of dPRL and its antiangiogenic derivatives to fetal development in
women with T1D and in rats with MD. In diabetic placentas, we ob-
served a signiﬁcant increase in PRL gene expression in women and of
Dprp gene expression in rats. We also found increased expression at
the protein level of two antiangiogenic PRL fragments in the women
and in rats. To our knowledge, this is the ﬁrst report to describe PRL
and its fragments in diabetic placentas.
Masumoto et al. showed a signiﬁcant increase of placental antian-
giogenic PRL fragments in cases of pregnancy-induced hypertension
[29]. It is noteworthy that none of our cases with T1D experienced
pregnancy complications, such as preeclampsia or pregnancy-induced
hypertension.
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or in combination with NCT in order to achieve less severe diabetes
[30]. STZ-treated rats arewidely used for inducing diabetes butwith dif-
ferent results of generated hyperglycemia ﬂuctuating from severe
(N300 mg/dl) [31] to mild (120–300 mg/dl) [32] depending on the
STZ dose or on the time of injection. Obtainingmoderate hyperglycemia
in rodents treated with low doses of STZ is difﬁcult and may be related
to the interaction of polygenic and nutritional factors as maternal diet
[33] that leads to different responses to diabetogenic agent in beta-
cells. To circumvent this question, we chose another strategy by
injecting STZ followed by NCT for ensuring a relative protective effect
on beta-cells with a partial destruction [34] and guaranteeing a mild
diabetic status in our animals. This model has been recently used to
determinate the effects of mild mother's hyperglycemia on the fetal
growth and some hypothetical links between placental dysfunctions
and abnormal fetal growth [35]. In contrast with models of diabetes
usually described in the literature, the NCT–STZ treatment had no effect
on the viability of the fetus, induced no fetalmalformations or IUGR. The
dose of NCT used (250 mg/kg) was higher than the one used in our
study.
In these animals, placental Dprp gene expression was increased
when compared to controls, but placental gene expression of the
other members of the PRL family, especially PrlmRNA level, did not sig-
niﬁcantly change. The expression of some members of the PRL family
varies according to species [36]. Rat PRL has only 64% homology within
humans [37]. The genome contains 24 genes related to PRL in rats
whereas, humans have only a single constituent: PRL itself [36,38,39].
Rodent PRL family members can undergo sub-functions compared to
the whole function of human PRL [39]. In women, the increase of PRL
mRNA and of its cleaved forms levels was more pronounced than that
in diabetic pregnant rat. The difference did not rely on the severity of
diabetes. The expression ofDprp in STZ andNCT–STZ groupswas similar
whereas diabeteswasmore severe in STZ group. Nonetheless, hypergly-
cemia and/or other abnormalities that usually are associated with
diabetes such as inﬂammation, individually or together, could affect
the expression and maturation of PRL.
In our study, the higher rat PRL maternal plasma levels and yet no
difference in dPRL gene expression in diabetic rats suggests higher PRL
anterior pituitary-gland production. It has been shown that the decidua
produces large amounts of PRL, which can enter the amniotic ﬂuid [40],
but only a small portion enters thematernal blood [41,42]. In contrast to
the rats, we did not assess maternal PRL blood levels in the T1D or con-
trol women.
The exact role of DPRP in the control of gestation is not clear.
DPRP is a 29-kDa protein isolated in the decidua; it resides in the de-
cidual extracellular matrix and is a member of the PRL family [43].
Alam et al. have shown, in Dprp-null mice, that DPRP deﬁciency
interfered with pregnancy-dependent adaptations to hypoxia
and resulted in total pregnancy failure at D7.5 [44]. Our data
suggest that placental up-regulation of Dprp could be an adaptiveconsequence of diabetes for maintaining pregnancy in this deleteri-
ous situation.
In our study, amounts of 15- and 17-kDa PRL fragments were in-
creased in human placentas from the diabetic group. In the diabetic an-
imal models, two PRL fragments, of 14- and a 16-kDa, were highlighted.
Our results are in accordancewith the literature in rat and in human [18,
22,24,45]. Human PRL proteolysis generates vasoinhibins with distinct
molecular masses from that obtained with rodent hormone, identiﬁed
by N-terminal sequencing and mass spectrometry as corresponding to
15-kDa, 16.5-kDa, [23,24,45,46] and 17-kDa [24]. Studies have reported
that amounts of 14- or 16-kDa PRL are increased in the circulation,
urine, amniotic ﬂuid, or placenta in cases of preeclampsia because of
renal glomerulus or decidual local production [13,25,29]. No study has
yet demonstrated an increase of these fragments in MD either in the
placenta or ﬂuids. An increase of these fragments in the placenta could
lead to decreased angiogenesis or increased apoptosis, causing a hypox-
ic atmosphere as observed in MD [47].
In line with this hypothesis, placental histology showed a
hypovascularization with a reduction in vascular surfaces and cap-
illary density with small capillary diameter in both species, which
could be caused by a defect in the angiogenesis mechanisms. T1D inﬂu-
ences placental microvascular bed by change size and course of capil-
laries, and altered structure of villous stroma [48]. The development of
the placenta is different between insulin-dependent diabetic pregnan-
cies if fetal macrosomia or maternal hypertensive disorders are present
with partial transformation of the spiral arteries [49]. Little is known on
the placenta of low birth offspring weight in T1D, especially when any
maternal complication as a microvascular one or a hypertension was
found as in our study. Placental efﬁciency in women was surprisingly
similar in all groups despite the placental hypovascularization, but MD
inﬂuences the placental structure in a complex manner. For the rats,
our results on placental hypovascularization are in agreementwith pre-
vious studies [50]. The reduction in the speciﬁc diffusing capacity of the
villous membrane may contribute to the fetal hypoxia and increased
fetal and neonatal morbidity associated with diabetes.
In addition, in women with preeclampsia, a linear dose–response
pattern between values of each of the vasoinhibins and the risk of SGA
has been demonstrated [13]. In this respect, while data support an in-
creased cleavage of PRL in a diabetic status, we could not exclude that
increases in vasoinhibins could account for the increased risk of some
perinatal outcomes, such as a lower birth weight in diabetic offspring
or IUGR in our animal models as suggested in preeclampsia. At this
time, there is no hard evidence to support this relationship between
this and fetal growth.
We also found that placental BMP-1 gene expression was increased
in women and in rats and could lead to increased PRL proteolysis in
the placenta. In contrast, CTSD gene expression was not affected in our
study. We do not exclude the possibility that CTSD, and perhaps other
proteases, such as MMPs, Kallikrein, and carboxypeptidases may be
involved to some extent in processing PRL.
In conclusion, the levels of members of the PRL family are modiﬁed
in the placenta during MD. We may speculate from our data that PRL
fragments are associated with the physiopathology of placental dys-
function in diabetes mellitus. The placental changes in these hormones
could impact on intrauterine fetal development.Contribution statement
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